<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ocular effects of hypertension</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ocular effects of hypertension</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Ocular effects of hypertension</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raymond R Townsend, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Law, MD, FACP</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A number of ocular abnormalities are directly or indirectly associated with hypertension [<a href="#rid1">1,2</a>]. These include some that are a direct consequence of elevated blood pressure, including hypertensive retinopathy, choroidopathy, and optic neuropathy. With other abnormalities, hypertension is a significant risk factor, including retinal vein and artery occlusion, retinal artery emboli, and diabetic retinopathy. In addition, hypertension may accelerate nonvascular eye disease, including age-related macular degeneration and glaucoma.</p><p class="headingAnchor" id="H2"><span class="h1">OCULAR DISEASES DIRECTLY RELATED TO HYPERTENSION</span><span class="headingEndMark"> — </span>Fundoscopy should be part of the physical examination on every patient with newly diagnosed hypertension since the retina is the only part of the vasculature that can be visualized noninvasively. Pupillary dilatation with a short-acting mydriatic (eg, <a class="drug drug_general" data-topicid="10028" href="/z/d/drug information/10028.html" rel="external">tropicamide</a> 1%) is almost always useful since the mild changes are hard to quantify, even with retinal photography [<a href="#rid3">3</a>]. Newer approaches to retinal imaging, such as optical coherence tomography angiography (OCTA), may also be useful in evaluating hypertensive retinopathies [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/3849.html" rel="external">"Initial evaluation of adults with hypertension", section on 'Physical examination'</a>.)</p><p>The most common ocular diseases directly related to hypertension are progressively increasing retinal microvascular changes, which are subsumed under the name "hypertensive retinopathy." Classically, the features are divided into four degrees, and their morphological classification has been widely used [<a href="#rid5">5</a>]. However, a more pathophysiological division has been proposed and seems more logical [<a href="#rid3">3,6</a>]. This three-degree classification includes mild, moderate, and severe (<a class="graphic graphic_diagnosticimage graphicRef104437" href="/z/d/graphic/104437.html" rel="external">image 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Mild – Retinal arteriolar narrowing related to vasospasm, arteriolar wall thickening or opacification, and arteriovenous nicking, referred to as "nipping" (<a class="graphic graphic_diagnosticimage graphicRef104437" href="/z/d/graphic/104437.html" rel="external">image 1</a>) [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate – Hemorrhages, either flame or dot-shaped, cotton-wool spots, hard exudates, and microaneurysms (<a class="graphic graphic_diagnosticimage graphicRef104437" href="/z/d/graphic/104437.html" rel="external">image 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe – Some or all of the above, plus optic disc edema (<a class="graphic graphic_diagnosticimage graphicRef104437" href="/z/d/graphic/104437.html" rel="external">image 1</a>). The presence of papilledema mandates rapid lowering of the blood pressure. Symptoms of papilledema are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5241.html" rel="external">"Overview and differential diagnosis of papilledema"</a>.)</p><p></p><p>Generalized narrowing and nicking are related to current and previous blood pressure levels; by comparison, focal narrowing, hemorrhages, and exudates are related only to current blood pressure levels [<a href="#rid7">7</a>].</p><p>Retinal arterial narrowing, a predictor of the future development of hypertension, is linked to nonocular systemic vascular diseases, particularly stroke [<a href="#rid8">8,9</a>]. In a study of 2907 hypertensives who had gradable retinal photographs and were followed for an average of 13 years, hypertensive retinopathy predicted the long-term risk of stroke, independent of the level of blood pressure [<a href="#rid10">10</a>]. Substantial evidence also exists for the association with coronary heart disease, left ventricular remodeling, and kidney damage [<a href="#rid11">11-14</a>].</p><p>The presence of hypertensive retinopathy should serve as an additional stimulus to ensure adequate control of hypertension. With good control, retinopathy may regress, providing an easily obtained indicator of success [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H3"><span class="h1">HYPERTENSION AS A RISK FACTOR FOR OCULAR DISEASE</span><span class="headingEndMark"> — </span>Hypertension increases the risk of a number of ocular diseases. The most common is diabetic retinopathy, which is also the most common cause of blindness in developed societies. In a multiethnic cohort in the United States, retinopathy was found in 33 percent of diabetics over age 40 years, 8 percent of whom had vision-threatening retinopathy [<a href="#rid16">16</a>]. Multiple factors may be involved in the added risk of hypertension to the development and progression of diabetic retinopathy, including increased endothelial damage [<a href="#rid17">17</a>].</p><p>Fortunately, good control of hypertension can reduce the threat of diabetic retinopathy, independent of control of hyperglycemia [<a href="#rid18">18</a>]. In the United Kingdom Prospective Diabetes Study, the risk of retinopathy was reduced 10 percent for each 10 mmHg lower systolic blood pressure [<a href="#rid18">18</a>]. Goal blood pressure and choice of antihypertensive therapy in patients with diabetes and diabetic retinopathy are discussed elsewhere in detail. (See  <a class="medical medical_review" href="/z/d/html/1773.html" rel="external">"Diabetic retinopathy: Prevention and treatment", section on 'Good blood pressure control'</a> and  <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p>Other ocular diseases wherein hypertension serves as a risk factor include retinal venous and arterial occlusion, retinal emboli, retinal macroaneurysm, and anterior ischemic optic neuropathy [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/15264.html" rel="external">"Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5236.html" rel="external">"Central and branch retinal artery occlusion"</a> and  <a class="medical medical_review" href="/z/d/html/5233.html" rel="external">"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">OCULAR DISEASES WHEREIN HYPERTENSION MAY BE A RISK FACTOR</span><span class="headingEndMark"> — </span>The risk for two of the more common causes of vision loss, age-related macular degeneration and glaucoma, may be increased by the presence of systemic hypertension. Although cross-sectional data support an association [<a href="#rid19">19,20</a>], the evidence is not conclusive. It should be noted that systemic hypotension, especially at night from excessive antihypertensive therapy, has been shown to further reduce blood flow to the optic nerve, accentuating the damage of high intraocular pressure from glaucoma [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/6909.html" rel="external">"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>The most common ocular diseases directly related to hypertension are progressively increasing retinal microvascular changes, which are subsumed under the name "hypertensive retinopathy." The three-degree classification includes mild, moderate, and severe disease. The presence of papilledema mandates rapid lowering of the blood pressure. (See <a class="local">'Ocular diseases directly related to hypertension'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension increases the risk of a number of ocular diseases, with the most common being diabetic retinopathy. Other ocular diseases wherein hypertension serves as a risk factor include retinal venous and arterial occlusion, retinal emboli, retinal macroaneurysm, and anterior ischemic optic neuropathy. (See <a class="local">'Hypertension as a risk factor for ocular disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk for two of the more common causes of vision loss, age-related macular degeneration and glaucoma, may be increased by the presence of systemic hypertension. (See <a class="local">'Ocular diseases wherein hypertension may be a risk factor'</a> above.)</p><p></p><p class="headingAnchor" id="H238523112"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Norman M Kaplan, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wong TY, Mitchell P. The eye in hypertension. Lancet 2007; 369:425.</a></li><li><a class="nounderline abstract_t">Gudmundsdottir H, Taarnhøj NC, Strand AH, et al. Blood pressure development and hypertensive retinopathy: 20-year follow-up of middle-aged normotensive and hypertensive men. J Hum Hypertens 2010; 24:505.</a></li><li><a class="nounderline abstract_t">Wong TY, Mitchell P. Hypertensive retinopathy. N Engl J Med 2004; 351:2310.</a></li><li><a class="nounderline abstract_t">Shaw LT, Khanna S, Chun LY, et al. Quantitative Optical Coherence Tomography Angiography (OCTA) Parameters in a Black Diabetic Population and Correlations with Systemic Diseases. Cells 2021; 10.</a></li><li><a class="nounderline abstract_t">Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1974; 268:336.</a></li><li><a class="nounderline abstract_t">Downie LE, Hodgson LA, Dsylva C, et al. Hypertensive retinopathy: comparing the Keith-Wagener-Barker to a simplified classification. J Hypertens 2013; 31:960.</a></li><li><a class="nounderline abstract_t">Sharrett AR, Hubbard LD, Cooper LS, et al. Retinal arteriolar diameters and elevated blood pressure: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999; 150:263.</a></li><li><a class="nounderline abstract_t">Wong TY, Klein R, Sharrett AR, et al. Retinal arteriolar diameter and risk for hypertension. Ann Intern Med 2004; 140:248.</a></li><li><a class="nounderline abstract_t">Wong TY, Klein R, Couper DJ, et al. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet 2001; 358:1134.</a></li><li><a class="nounderline abstract_t">Ong YT, Wong TY, Klein R, et al. Hypertensive retinopathy and risk of stroke. Hypertension 2013; 62:706.</a></li><li><a class="nounderline abstract_t">Wong TY, Klein R, Sharrett AR, et al. Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The Atherosclerosis Risk in Communities Study. JAMA 2002; 287:1153.</a></li><li><a class="nounderline abstract_t">Cheung N, Bluemke DA, Klein R, et al. Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis. J Am Coll Cardiol 2007; 50:48.</a></li><li><a class="nounderline abstract_t">Wong TY, Coresh J, Klein R, et al. Retinal microvascular abnormalities and renal dysfunction: the atherosclerosis risk in communities study. J Am Soc Nephrol 2004; 15:2469.</a></li><li><a class="nounderline abstract_t">Shantha GP, Kumar AA, Bhaskar E, et al. Hypertensive retinal changes, a screening tool to predict microalbuminuria in hypertensive patients: a cross-sectional study. Nephrol Dial Transplant 2010; 25:1839.</a></li><li><a class="nounderline abstract_t">Bock KD. Regression of retinal vascular changes by antihypertensive therapy. Hypertension 1984; 6:III158.</a></li><li><a class="nounderline abstract_t">Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 2006; 141:446.</a></li><li><a class="nounderline abstract_t">Hsueh WA, Anderson PW. Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus. Hypertension 1992; 20:253.</a></li><li><a class="nounderline abstract_t">Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317:703.</a></li><li><a class="nounderline abstract_t">Hyman L, Schachat AP, He Q, Leske MC. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol 2000; 118:351.</a></li><li><a class="nounderline abstract_t">Mitchell P, Lee AJ, Rochtchina E, Wang JJ. Open-angle glaucoma and systemic hypertension: the blue mountains eye study. J Glaucoma 2004; 13:319.</a></li><li><a class="nounderline abstract_t">Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol 1994; 117:603.</a></li></ol></div><div id="topicVersionRevision">Topic 3859 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17276782" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The eye in hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20010619" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Blood pressure development and hypertensive retinopathy: 20-year follow-up of middle-aged normotensive and hypertensive men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564546" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hypertensive retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33806492" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Quantitative Optical Coherence Tomography Angiography (OCTA) Parameters in a Black Diabetic Population and Correlations with Systemic Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4616627" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Some different types of essential hypertension: their course and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23449021" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hypertensive retinopathy: comparing the Keith-Wagener-Barker to a simplified classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430230" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Retinal arteriolar diameters and elevated blood pressure: the Atherosclerosis Risk in Communities Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14970147" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Retinal arteriolar diameter and risk for hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11597667" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23940194" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hypertensive retinopathy and risk of stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11879113" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The Atherosclerosis Risk in Communities Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17601545" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15339997" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Retinal microvascular abnormalities and renal dysfunction: the atherosclerosis risk in communities study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20054024" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hypertensive retinal changes, a screening tool to predict microalbuminuria in hypertensive patients: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6519755" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Regression of retinal vascular changes by antihypertensive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490489" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diabetic retinopathy in a multi-ethnic cohort in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1639468" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9732337" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10721957" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15226661" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Open-angle glaucoma and systemic hypertension: the blue mountains eye study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8172267" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
